Is the MediWound (MDWD) investment thesis intact?

It is under pressure. Readouts currently rates the MediWound Thesis Challenged. Pending equity raise adds liquidity; VALUE's sample size reassessment remains central.

What is the next catalyst for MediWound (MDWD)?

The next dated event is Trial start for EscharEx, expected Q4 2026, as stated by the company. Also ahead: Phase 3 enrollment complete (VALUE) for EscharEx, expected Q1 2027.

How long will MediWound's cash last?

MediWound has said its cash will fund operations beyond Mar 2027 (guidance as of March 5, 2026).

MDWDMediWound Ltd.

⚡

MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares - GlobeNewswire

GlobeNewswire · Nov 5, 9:05 PM

⚡

MediWound announces $15 million share offering - Investing.com

Investing.com · Nov 3, 10:14 PM

⚡

MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares - GlobeNewswire

GlobeNewswire · Nov 3, 9:40 PM

ChallengedLast material event Aug 13, 2026 · Updated Nov 4, 2026

Pending equity raise adds liquidity; VALUE's sample size reassessment remains central

MediWound sells NexoBrid, an approved enzymatic product that removes dead tissue from burns, and is developing EscharEx for chronic wounds such as venous leg ulcers; EscharEx is not approved.

MediWound's case rests on investigational EscharEx for chronic wounds, alongside approved burn product NexoBrid. VALUE targets 216 venous leg ulcer patients, with interim sample size reassessment and enrollment completion expected by the end of the first quarter of 2027. NexoBrid adoption supports the business, while expanded-facility supply awaits approval. Cash was $36 million at June 30, 2026, after $20 million of first-half burn. A pending approximately $15 million gross equity offering would add liquidity with dilution, but funding through VALUE results remains uncertain.

Thesis checklist

1 risk needs attention

Select a row for evidence

What must be trueStateNext proof

VALUE finishes enrolling without a large sample size increaseAwaiting evidenceInterim sample size reassessment and enrollment completion, expected by the end of the first quarter of 2027.Next: Interim sample size reassessment and enrollment completion, expected by the end of the first quarter of 2027.

Why it is in this state

The evidence, what would weaken it and the source filing

NexoBrid revenue and supply growAwaiting evidenceCompletion of EMA-requested facility modifications, expected in the fourth quarter of 2026, and initial MSA revenue.Next: Completion of EMA-requested facility modifications, expected in the fourth quarter of 2026, and initial MSA revenue.

Why it is in this state

The evidence, what would weaken it and the source filing

Cash lasts to the Phase III readoutAt riskOffering close, actual net proceeds, and an updated cash balance alongside VALUE spending needs.Next: Offering close, actual net proceeds, and an updated cash balance alongside VALUE spending needs.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

VALUE interim sample size reassessment

Tests: VALUE finishes enrolling without a large sample size increase

By the end of the first quarter of 2027

Does the reassessment keep VALUE's patient requirement manageable and allow enrollment to finish as planned?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

ChallengedCurrentCorporate

-2.7%Aug 13, 2026

Pending equity raise adds liquidity; VALUE's sample size reassessment remains central

IntactFinancial

-14.1%May 27, 2026

NexoBrid's $197M BARDA contract anchors MediWound's commercial case; whether manufacturing regulatory approval unlocks full revenue potential is the deciding test

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Venous leg ulcers

EscharEx · 1 upcoming

Phase 3 Enrollment: CompletionVALUE

Mid 2026Q1 2027

Pressure ulcers

EscharEx · 1 upcoming

Study InitiationIIT

Q4 2026

Thermal burns

NexoBrid · 1 upcoming

Approval of commercial supply from the expanded facility

H2 2027

Trauma· blast and friction injuries

NexoBrid · 1 completed

BARDA multi-year program agreement

Reported Apr 2, 2026

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the MediWound (MDWD) investment thesis intact?: It is under pressure. Readouts currently rates the MediWound Thesis Challenged. Pending equity raise adds liquidity; VALUE's sample size reassessment remains central.
What is the next catalyst for MediWound (MDWD)?: The next dated event is Trial start for EscharEx, expected Q4 2026, as stated by the company. Also ahead: Phase 3 enrollment complete (VALUE) for EscharEx, expected Q1 2027.
How long will MediWound's cash last?: MediWound has said its cash will fund operations beyond Mar 2027 (guidance as of March 5, 2026).

Disease areas: Skin diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.